Nyowani Mushonga Wekushandisa kune Varwere vane Follicular Lymphoma

JW Therapeutics, kambani yakazvimirira yebiotechnology yakatarisana nekugadzira, kugadzira nekutengesa zvigadzirwa zvema cell immunotherapy, yakazivisa kuti National Medical Products Administration (NMPA) yekuChina yakagamuchira iyo yekuwedzera New Drug Application (sNDA) yeayo anti-CD19 autologous chimeric antigen receptor T ( CAR-T) cell immunotherapy chigadzirwa Carteyva® (relmacabtagene autoleucel jekiseni) yekurapa varwere vakuru vane relapsed kana refractory follicular lymphoma (r/r FL). Ichi ndicho chechipiri chekushambadzira chikumbiro paCarteyva® chakatumirwa neJW Therapeutics, uye inotarisirwa kuve yekutanga sero therapy chigadzirwa chakabvumidzwa muChina chekurapa r/r FL varwere. Carteyva® yakapihwa Breakthrough Therapy Designation neNMPA munaGunyana 2020.

Iyo sNDA yakatsigirwa nemhedzisiro yekiriniki kubva kuboka B reruwoko rumwe, akawanda-pakati, pivotal kudzidza (RELIANCE kudzidza) paCarteyva® muvarwere vakuru vane kudzokazve kana refractory B cell non-hodgkin lymphoma muChina. Mhedzisiro yezvidzidzo yakapihwa pa63rd American Society of Hematology (ASH) Musangano Wepagore muna Zvita 2021. The cohort B zvawanikwa zvakaratidza kuti Carteyva® yakaratidza yakakwira zvakanyanya yekugara kwenguva refu kwechirwere chemhinduro (Best Complete Response Rate uye Yese Response Rate pamwedzi ye3 yaive. 92.6% uye 100%, zvichiteerana) uye inodzoreka CAR-T inobatanidza chepfu muvarwere vane r / r FL (42.9% uye 17.9% yevarwere vaive nechero giredhi Cytokine Release Syndrome (CRS) uye Neurotoxicity (NT), nepo 0% uye 3.6% yevarwere vakawana CRS uye NT yeGiredhi 3 kana pamusoro).

Muzvinafundo Yuqin Song, Chiremba Mukuru weDhipatimendi reLymphoma paPeking University Cancer Hospital, Director weChina Society of Clinical Oncology (CSCO), akacherekedza pa63rd American Society of Hematology (ASH) Musangano Wepagore: "RELIANCE mhedzisiro yeongororo inoratidza kuti Carteyva® yakaratidza. Kubudirira kwakanyanya uye kuchengetedza chimiro muvarwere vane r/r FL uye isu tiri kutarisira kubvumidzwa kweSNDA muChina. "